George R. Siber

George R. Siber, M.D., is an internationally recognized vaccine expert with 40 years of experience in developing numerous innovative vaccines. From 1975 to 1996, Dr. Siber served on the Faculty of Medicine at Harvard University as Assistant and Associate Professor of Medicine based at the Dana Farber Cancer Institute. Concurrently, from 1982 to 1996, Siber was Director of the Massachusetts Biologic Laboratories. Under his leadership the laboratory developed specific immune globulins to CMV (Cytogam) and to RSV (Respigam) the precursor product to Synagis.

From 1996 to 2007, Siber was Executive Vice President and Chief Scientific Officer of Wyeth Vaccines Research, overseeing the development, approval, and marketing of six innovative childhood vaccines including Prevenar, the first pneumococcal conjugate vaccine, Meningitec, the first Meningococcal C conjugate vaccine, Rotashield, the first rotavirus vaccine and FluMist, the first live nasal influenza vaccine.

Dr. Siber currently serves on the Board of Directors of Genocea and on the Scientific Advisory Boards of CureVac, ILiAD, Valneva, Vaxess, AdVaccine, CanSino, Vaxxinity and Clover. Dr. Siber has received multiple awards including the 2016 Albert Sabin Gold Medal in vaccinology.